We have previously reported the presence of Dlxin-1, a member of the melanoma antigen gene (MAGE) family, in the brain and showed its function as a cell cycle arrest protein, suggesting that Dlxin-1 may have anti-proliferative functions in rapidly growing tumors. Using the cancer stem cell hypothesis, which attributes the initiation and progression of brain tumors to the cancerinitiating stem cells, we have investigated the role of Dlxin-1 in the glioma stem cells propagated by us as a cell culture system comprising of HNGC-2 cells. Our studies provide evidence about the role of Dlxin-1 as an anti-tumorigenic protein in the highly chemo-resistant glioma stem cells. Next, we show that these anti-proliferative effects are manifested by Dlxin-1 through down regulation of the activities of MMP-2 and MMP-9, and through interaction of Dlxin-1 with its target protein P311 that is involved in glioma cell invasion. In summary, we establish the roles for Dlxin-1, one as an anti-tumorigenic and anti-invasive protein in highgrade gliomas and the other as an inducer of differentiation of glioma stem cells. These two attributes, in conjunction, result in conversion of the drug-resistant brain tumor stem cells to the tumor-attenuated cells that may now be more amenable to effective therapeutic targeting.
Introduction
Among the different types of brain tumors, glioblastoma multiforme (GBM) is one of the most common and malignant type of brain tumor that shows resistance to varied treatment modalities that include chemo-and radiotherapy. Recent studies provide evidence about the existence of a small subpopulation of cells within the glioma, tumor, termed as cancer stem cells (CSCs), brain tumor-initiating cells (BTICs) or glioma stem cells that drive tumor progression and confer therapeutic resistance. [1] [2] [3] [4] These brain tumor-initiating stem cells display the properties of self-renewal and multi-lineage differentiation, and many express the cancer stem cell marker CD133. 2 The enhanced expression of CD133 is shown to correlate with poor prognosis in gliomas. 5 The neurotrophin receptor-interacting MAGE homolog (NRAGE) also known as Dlxin-1 or MAGED1 is a member of the Type II MAGE family of proteins. Members of this family are broadly expressed during development and are characterized by presence of a common 200 amino-acids MAGE homology domain. NRAGE is involved in a myriad of cellular functions ranging from cell cycle regulation, adhesion, differentiation, renal morphogenesis to developmental apoptosis in vivo. [1] [2] [3] [4] [5] [6] The interactions of NRAGE with the highaffinity p75NGF receptor or to the netrin-1 receptor UNC5H1 7 often facilitates apoptotic signaling in vitro. 7 The deletion of NRAGE in vivo is frequently manifested in the form of defects in developmental apoptosis of sympathetic neurons of the superior cervical ganglia. 8 We earlier reported about the development and characterization of a glioma stem cell-line HNGC-2, enriched with a tumor-initiating stem cell population. 9, 10 Our studies indicated that these cells are highly chemo-and radio-resistant, and thereby represent an ideal cell system for studying therapeutic potential of molecules with antiproliferative function. Although there are few reports about the anti-tumorigenic and anti-invasive effects of NRAGE on pancreatic cancer, melanomas 11 and in breast cancers, 12 its effects on gliomas and particularly on glioma stem cells are not known. With an aim to evaluate the role of Dlxin-1 on glioma stem cells, we overexpressed it in these cells and investigated the effects of its overexpression on their self-renewal, proliferative, tumorigenic and differentiation potential. We in this study present a representative data of the effects of Dlxin-1 on glioma stem cells HNGC-2, whereas we obtained similar effects of Dlxin-1 on two other glioma stem cells NSG11 and NSG12 developed by us. In this study, we unequivocally establish the ability of Dlxin-1 to effectively inhibit growth and invasion of glioma stem cells. Next, we show that Dlxin-1 besides inhibiting growth at both the in vitro and in vivo levels also induces differentiation of glioma stem cells into glial fibrillary acidic protein (GFAP)-positive cells. We further demonstrate that a protein P311, involved in glioma cell invasion and motility, is a novel interacting partner of Dlxin-1 and their physical interaction leads to the growth inhibitory effect of Dlxin-1 thereby bestowing a novel therapeutic role for Dlxin-1 in glioma that may also arise from CSCs.
Materials and methods
Cell culture Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37 1C in 5% CO 2 . Long-term cultures NSG11 and NSG12 were generated from surgical tumor tissue specimens of glioma samples obtained from local hospital. Informed consent was sought from patients. The study was approved by the bioethics committee of NCCS (Pune, India).
Transfection assays
For transfections, cells were plated at a density of 1 Â 10 3 cells in 35-mm tissue culture dishes, cultured in growth medium for 16 h and transfected with either 1 mg of pTarget-Dlxin-1 cDNA or with pTargetT plasmid DNA (EV) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) using manufacturer's protocol. Stable transfectant clones expressing Dlxin-1 were selected with 700 mg/ml Geneticin (Amersham Biosciences, Piscataway, NJ) and developed into stable cell lines. Cells transfected with empty vector served as control in all the experiments. For transfections with small-interfering RNAs (siRNAs), 1 Â 10 3 cells were plated in 24-well plates. The cells were transfected with Dlxin-1 siRNA (50 nM) according to the manufacturer's instructions (NEB, Ipswich, MA). The siRNA used in the study to knockdown Dlxin-1 gene expression consisted of pools of three to five Dlxin-1-specific 19-25 nucleotide siRNAs.
Semi-quantitative and quantitative polymerase chain reaction Human Universal, fetal brain and adult whole brain cDNAs were used in expression studies for Dlxin-1. For cell lines, total cellular RNA was extracted by TRIzol Reagent (Invitrogen) and treated with RQ1 RNase-free DNase according to manufacturer's instructions (Promega, Madison, WI). Total RNA was reverse transcribed to generate cDNA using RT-PCR kit (Promega). The cDNA pool was subjected to semi-quantitative PCR with genespecific primers using Taq DNA polymerase (Takara, Shiga, Japan). Matrix metalloproteinases (MMPs) MMP-2 and MMP-9 expressions were analyzed from cells transfected with Dlxin-1 siRNA and processed for expression using gene-specific primers For real-time PCR analyses, the cDNA pool was subjected to RT-qPCR (Applied Biosystems, Carlsbad, CA) on the ABI 7500 Fast Real-Time PCR system (Applied Biosystems). Specificity of primers was determined by melt curve analysis. Primers were purchased from (IDT Technologies, Novato, CA). The sequence of primers is enlisted in Supplementary Table S2 . Standard curves were constructed with serial dilutions of specific PCR products.
Colony-forming units assay
Approximately 5 Â 10 3 cells were plated in 35-mm culture dishes for transfections with Dlxin-1 cDNA or pTarget DNA (EV). After 2 weeks, the culture dishes were washed in phosphate-buffered saline (PBS) and the colonies developed were stained with 0.5% (v/v) crystal violet in 25% methanol. After 15 min, the dishes were washed with water and allowed to dry, and the colonies obtained were counted using Gene Tools Software from Syngene (Gene Company, Chai Wan, Hong Kong).
Cell proliferation assay
Cell proliferation was determined with MTT assay by seeding 3000cells/well of HNGC-2 cells. 13 Absorbance measurements were taken at every 24 h interval over a 5-day period.
Transwell migration assay Migration assay in vitro was performed in 24-well cellculture plates using Matrigel Invasion Chambers of 8.0-mm pore size membrane using manufacturer's protocol (BD Biosciences, San Jose, CA) and method described by Albini et al, 14 in which about 5 Â 10 4 cells in 0.5 ml of complete Dulbecco's modified Eagle's medium were seeded in the upper compartment of each well of the test and control inserts. Dulbecco's modified Eagle's medium with 5% fetal calf serum served as a chemoattractant in the lower compartments of both inserts. The plate was incubated for 22 h. After incubation, the non-invading cells on the upper surface were mechanically scrubbed and removed, and the filters were fixed and stained with Giemsa for 30 min and washed to remove the excess stain. Migrated cells on the bottom side of the membrane were counted in 10 different fields to acquire the average number of cells per cell line. Each experiment was performed in triplicates and repeated at least twice under independent culture conditions.
Wound-healing assay
Cell migration in vitro was determined by the wound closure migration assay. 15 Briefly, a pipette tip was used to create a wound on the confluent layer of cells and the cells were examined after 0 and 24 h at Â 10 magnification using an inverted microscope (Olympus America, Center Valley, NY). Migration distance was determined using Image-Pro software 6 (Olympus America).
Soft agar assay
The clonogenic potential of cell lines was determined by soft agar assay using 1500 cells. 19 Colonies were assayed after 7 days using Â 10-objective and counted in 10 different fields to acquire the average number of colonies per cell line.
Tumorigenicity and engraftment assays
Cells ranging from 1 Â 10 3 to 1 Â 10 6 of each cell type were injected subcutaneously into young female NOD-SCID mice, and closely observed for tumor development and progression for a maximum period of up to 3 months. For determining tumor kinetics, the tumor size was measured using Vernier calipers, and tumor volume was calculated with the formula: 4/3p (O major axis/2 Â minor axis/2). 3 Mice that did not develop tumors up to 3 months were killed. For implantation studies within the brain of NOD-SCID mice, cells were stably transfected with pEGFP-N1 vector (Clontech, Mountain View, CA) using Lipofectamine 2000. Hygromycin-resistant colonies were selected after 2 weeks and expanded into stable cell lines. The green fluorescent protein (GFP)-expressing cells corresponding to 1 Â 10 3 cells in PBS were injected intracranially in nude mice, and animals were examined very closely for behavioral changes such as abnormal movement and paralysis. Animal experimentation was done in accordance with the rules and regulations of the institutional animal ethics committee of NCCS.
Immunohistochemistry of mouse brain
The mouse brain tissues were examined for tumor focii using inverted fluorescence microscope with GFP filter for detecting the presence of GFP-positive cells within the brain tissue. A part of the tissue was fixed in 4% formalin solution and processed for immunocytochemical analyses. The sections were stained with antibodies to GFAP, Ki67 (Millipore, Billerica, CA), CD31 (Santa Cruz, Santa Cruz, CA) and VEGF (Abcam, Cambridge, UK) followed by their detection using Alexa Fluor dyes conjugated to corresponding species-specific secondary antibodies. 16 Also, the sections were stained with hematoxylin and eosin for histopathological analyses.
Immunofluorescence staining
The cells were seeded at low density on glass coverslips and grown for 24 h to achieve semi-confluent cultures. The cells were fixed with methanol for 10 min at 4 1C, washed with PBS, and blocked with 1% bovine serum albumin in PBS. The cells were incubated with the following primary antibodies (1:100 dilution) for 1 h at room temperature: GFAP, Ki67 and P311(C5orf13) (Sigma-Aldrich, St Louis, MO). Later, the cells were incubated with corresponding secondary antibodies conjugated with either Alexa Fluor 488 or Alexa Fluor 595 (Molecular Probes, Eugene, OR) for 45 min at room temperature (1:50 dilution). Appropriate isotypic antibodies served as negative controls. To visualize nuclei, the cells were incubated with 4 0 ,6-diamidino-2-phenylindole (Sigma) for 10 min at room temperature before being mounted with anti-fade 1,4-diazobicyclo-2,2,2-octane in mounting medium (Sigma). Confocal images were observed and acquired using LSM 510 Meta Confocal Microscope (Carl Zeiss MicroImaging GmbH, Go¨ttingen, Germany). Images were captured using AxioCAM HR digital camera and processed using the AxioVision Zeiss Digital Image Processing Software (Carl Zeiss MicroImaging GmbH).
Western blotting and immunoprecipitation analyses
Cells were lysed in 1 Â cell lysis buffer (Cell Signaling, Danvers, MA) containing 1 Â protease inhibitor cocktail (Sigma-Aldrich). Protein samples were separated on SDS-PAGE (10%) and electrotransferred onto polyvinylidene fluoride membranes (Amersham BioSciences). The expression of proteins was analyzed using antibodies to p21, phospho-p21 (Thr145) (Cell Signaling). The blots were incubated with appropriate secondary antibodies conjugated to Horseradish peroxidase (Cell Signaling) and developed using Super Signal West maximum sensitivity substrate (Pierce, Rockford, IL). The protein levels were normalized by re-probing the blots with antibody to b-actin (MP Biomedicals, Solon, OH). For immunoprecipitation studies, 1 Â 10 7 cells were pelleted down with 5 ml of ice-cold 1 Â PBS. Extracts were prepared using 1 Â RIPA buffer containing protease inhibitor cocktail, and estimated using Lowry's reagent. Protein lysate (500 mg) was taken and precleared with agarose G beads for 30 min at 4 1C. Lysates were incubated either with Dlxin-1 antibody or with P311 antibody for 4 h followed by overnight incubation with Protein G beads at 4 1C. The immunoprecipitation complexes were washed using 1 Â cell lysis buffer and the beads were heated in 1 Â SDS buffer. Pulled-down proteins were loaded onto a 16% Tricine gel and electrophoresis was performed for 6 h at 60 V. The gel was transferred on to a 0.22-mm polyvinylidene fluoride membrane and blotted for Dlxin-1 or P311 proteins.
MMP assays and zymography
The activities of MMPs were assayed by gelatin zymography on SDS-PAGE gels impregnated with 0.1% gelatin (w/v). Equal quantity of protein was mixed with 5 Â Laemelli's sample buffer and analyzed by electrophoresis. The gel was washed twice with washing buffer for 30 min and incubated overnight at 37 1C in renaturation buffer and stained with 0.2% Coomasie Brilliant Blue R-250 in 40% iso-propanol and destained using 7% glacial acetic acid.
Microarray analysis
The RNA was extracted using Ambion RNA Isolation kit (Ambion, Austin, TX) using manufacturer's method. The total RNA quality and integrity was checked using a Bioanalyzer, and RNA samples showing absorbance value 260/280 ratioX2.0 were used for microarray-based studies. For gene expression profiling studies, RNA samples were labeled using Cy3 and carefully loaded into 60-mer oligonucleotides for human whole genome 44-K microarray slides (Agilent Technologies, Santa Clara, CA). The slides were hybridized overnight and then a high throughput scanning was performed to determine the Cy3 intensity distribution.
Methylation specific-polymerase chain reaction Genomic DNA was obtained from cell lines for methylation-specific PCR. Briefly, 2 mg of genomic DNA was subjected to bisulfite modification using Epitect bisulfite kit using manufacturer's instructions (Qiagen, Valencia, CA). After the bisulfite conversion, the products were purified through columns and analyzed by PCR. The primer pairs for methylation-specific PCR were designed for CpG island identification using primer design by MethPrimerExpress (Applied Biosystems). The PCR products were electrophoresed on 2% agarose gel stained with ethidium bromide and visualized under ultraviolet illumination.
Statistical analyses
All the results generated from three independent experiments with five replicates of each determination were performed, unless stated otherwise. Values in results and figures are means±s.d. In all experiments, Pp0.05 was considered significant.
Results
Lower levels of Dlxin-1 mRNA in glioma cell lines compared with brain tissues We in our earlier studies showed that Dlxin-1 was predominantly expressed as a 3.2 Kb transcript in fetal and adult brain tissues. 17 With an aim to investigate whether there is a differential level of expression of Dlxin-1 in normal brain-derived cells compared with brain tumors, we performed semi-quantitative RT-PCR analyses wherein we compared Dlxin-1 expression in normal human fetal and adult brain with its expression in established glioma cell lines such as LN-18, LN-229, U87/ MG and glioma stem cell-line HNGC-2. Our data indicated that, although Dlxin-1 mRNA was highly present in fetal and adult brain tissues its expression in human glioma cell lines though variable was quite low. Strikingly, the glioma CSCs HNGC-2 showed the least Dlxin-1 expression (Figure 1a ). Immunocytochemical studies indicated that Dlxin-1 was present as a predominant cytoplasmic protein and there were distinct differences in its protein expression levels in normal brain tissue compared with brain tumors of different grades (Figure 1b) . A representative analysis showed that, although Dlxin-1 was present in the normal fetal brain-derived cells and to a smaller extent in low-grade glioma culture NSG-12, its expression was negligible in CSCs representing GBM (Figure 1b ) and in representative GBM samples screened by us (data not shown), indicating that there existed an inverse co-relationship between increasing grade of glioma to levels of Dlxin-1. To analyze the effects of Dlxin-1 overexpression in HNGC-2 cells, we generated stable cell line of HNGC-2-Dlxin that overexpressed the transcript (Figure 1a ) and Dlxin-1 protein (Figure 1c) , and used it as a representative cell line for study. To understand whether differences in levels of Dlxin-1 expression in established glioma cell line such as LN18 and in the CSCs HNGC-2 could be ascribed to its promoter methylation status, we performed bisulfite treatment of the DNA followed by methylation-specific PCR. Our studies unveiled a homogenously methylated Dlxin-1 promoter in HNGC-2 cells, whereas LN18 cells showed an unmethylated promoter at the CpG locus (Supplementary Figure S1) , suggesting that epigenetic patterns most likely drive the expression of Dlxin-1 in glioma stem cells.
Dlxin-1 exerts anti-proliferative effects on glioma cells
The HNGC-2 cells are enriched with a high percentage of brain tumor-initiating stem cells and can be propagated as xenografts, in which these cells in lower numbers form Table S1 ). The human Universal cDNA and cDNAs derived from fetal brain and adult whole brain were from Clontech, whereas all the other cDNAs used in this study were from RNA extracted from cells. b-Actin served as an internal control. (b) The immunocytochemical localization of Dlxin-1 analyzed in cells derived from the human fetal brain, human neural stem cells HNGC-1, long-term culture of low-grade glioma NSG-12, and in established glioma cell lines LN229, LN18 and HNGC-2. (c) The Dlxin-1-overexpressing HNGC-2 cells show intense cytoplasmic expression of Dlxin-1(red). Nuclei were stained with DAPI (blue) (Scale, 10 mm).
intracranial tumors, resembling GBM upon transplantation into NOD-SCID mouse brain. Characteristically, the HNGC-2 cells show high expression of neural stem and progenitor markers such as CD133, nestin, Sox-2, Musashi-1, 10 and additionally share presence of ATPbinding cassette transporter G2 and exhibit aldehyde dehydrogenase activity (Supplementary Figure S2) , a feature of stem and progenitor cells 18 and now considered as a prognostic marker to predict metastasis in different tumors such as breast cancers. 23 The HNGC-2 control cells and their Dlxin-1-expressing counterparts were analyzed for their growth potential by MTT assay (Figure 2a, A) and for expression of the proliferation marker Ki67 (Figure 2a, B) . Although the HNGC-2 cells grew in an exponential manner over the 5-day period studied, the Dlxin-1-expressing HNGC-2 cells exhibited a much slower growth potential in MTT assay and possessed a lower percentage of cells expressing the proliferation marker Ki67. These findings exemplify the role of Dlxin-1 in growth suppression of glioma cells.
Next, we analyzed the effects of Dlxin-1 on cell growth in vitro by determining the colony-forming units scored over a 2-week period. We observed that Dlxin-1 induced a significant decrease in colony-forming potential of HNGC-2 cells with effects manifested in terms of a decrease in colony size (Figure 2b, A) as well as colony number by about 59 ± 4.52% (Figure 2b, B) . To further this study on effect of Dlxin-1 on in vitro transformation, we performed a soft agar assay using both the HNGC-2-EV and HNGC-2-Dlxin cells and counted the number of colonies growing on agar at day 8. Interestingly, the Dlxin-1 cells exhibited a decreased clonogenicity reflected at the level of both colony size and number, in which a decrease in colony number by 59.94 ± 5.08% was induced by Dlxin-1 (Figures 2c, A and B) . This indicated that Dlxin-1 was not only functioning as an anti-proliferative protein but more importantly was also acting as an inhibitor of cell transformation. Next, we determined the effect of Dlxin-1 on directional cell migration in vitro by wound closure migration assay, performed to estimate the migration and proliferation rates of cells under different culture conditions. Although the HNGC-2-EV cells within 24 h were able to repopulate the wound and showed increased cell migration, the HNGC-2-Dlxin cells were not able to do so in the same time frame analyzed (Figure 2d, A) . A 67.05±10.47% decrease in migratory ability was caused by Dlxin-1 compared with EV cells within 24 h (Figure 2d, B) , indicating that Dlxin-1 was effective in suppressing cellular motility in vitro. Our earlier studies have established the highly invasive nature of the HNGC-2 cells using the Matrigel penetration assay. 19 Here, we found that Dlxin-1 lowered the migration potential of HNGC-2 cells to 66.77 ± 4.91% compared with HNGC-2-EV cells (Figures 2e, A and B) performed over a 22 h interval. The effects of Dlxin-1 overexpression on glioma cells analyzed at the level of CFU assay, SAA assay, wound closure and in vitro migration assays revealed strong anti-proliferative and more importantly anti-invasive nature of Dlxin-1.
Suppression of tumorigenicity with Dlxin-1
To analyze whether decrease in proliferation potential, transforming ability and migratory capabilities exhibited in vitro by Dlxin-1, transcend to similar effects on tumor growth in vivo, tumorigenicity assays were performed by subcutaneous and intracranial injections of HNGC-2-Dlxin cells in immunocompromised NOD-SCID mice. Our earlier studies provided experimental evidence about the cancer stem cell nature of HNGC-2 cells in which we demonstrated that as few as 1000 cells were capable of rapidly forming a tumor at the site of injection. Also, the same number of HNGC-2 cells when implanted intracranially formed rapidly growing tumors within the brain in 6-8 days of implantation. , indicating that Dlxin-1 induced a 83.4 ± 1.655% decrease in tumor volume in all the mice examined (n ¼ 3) (Figures 3a, A and B) .
Existing reports about the role of MAGED1 as an inhibitor of angiogenesis in endothelial cells, 20 incited us to explore the effects of Dlxin-1 as an anti-angiogenic protein in the glioma stem cells. For this, we focused on studying the effects of Dlxin-1 on brain colonization and vascularization in murine orthotopic xenografts generated by individually injecting about 1000 cells of HNGC-2-EV and HNGC-2-Dlxin intracranially in NOD-SCID mice. Interestingly, although the HNGC-2 cells within 7-10 days of injection invaded the entire brain parenchyma, only a small number of HNGC-2-Dlxin cells colonized the brain tissue (Figure 3b) . A significant inhibition in blood vessel formation was evidenced in Dlxin-1 tumor xenografts, as analyzed by expression of endothelial markers CD31 and VEGF (Figure 3c, A) . Also, scanty Ki67 staining was observed in the brain tumor tissue sections injected with HNGC-2-Dlxin cells as compared with parental HNGC-2 cells re-affirming the role of Dlxin-1 in growth inhibition (Figure 3c, B) . Interestingly, the few HNGC-2-Dlxin-GFP cells that got implanted within the brain were highly differentiated as compared with HNGC-2-EV cells, as apparent from expression of differentiation marker GFAP in tumor tissue sections (Figure 3d , A) and in established cell line (Figure 3d, B) . These findings illustrate the role of Dlxin-1 as a growth suppressor and an anti-invasive protein with a potential to induce differentiation in vivo.
Dlxin-1 lowers p21 and MMP-2 expression in glioma cell lines
In response to DNA damage, p53 accumulates and functions as a sequence-specific DNA-binding protein, which positively regulates expression of several genes, including the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) . Although the nuclear accumulation of p21 frequently leads to cell cycle arrest, its cytoplasmic localization is highly correlated with overexpression of phosphop21 (Thr145) . 21 Various studies have shown that cytoplasmic localization of p21 and activation of p-p21 is often associated with poor prognosis in various cancers such as in breast cancer, glioma and leukaemia 22, 23 Studies suggest that p21 is phosphorylated by Akt, leading to increase in its expression levels, protein stabilization, translocation into the cytoplasm followed by chemoresistance and poor outcome. 24 Our earlier studies in HNGC-2 cells indicated the absence of nuclear p21, but its presence as a cytoplasmic protein. Hence, to understand whether p21 has any role in Dlxin-1-induced growth arrest, we analyzed p21 and p-p21 levels in HNGC-2 cells using both p21 (total) as well as phosphorylated p-p21 (Thr145) antibodies. We found that Dlxin-1 decreased p-p21 levels in HNGC-2 cells (Figure 4a ). We earlier showed that both nuclear p53 and p21 are not expressed in HNGC-2 cells causing a total collapse in the DNA repair functions in these cells. 10 The p-p21 is however localized to the cytoplasm in HNGC-2 cells. Our data indicated that Dlxin-1 effectively downregulated the levels of cytoplasmic p-p21 in these cells (Figure 4a ). As presence of cytoplasmic p21 is an independent prognostic factor in various cancers, novel therapeutic agents that target phosphorylation/cytoplasmic localization of p21 may also contribute to optimal treatment, further highlighting the role of Dlxin-1 as a therapeutic target in chemoresistant glioma stem cells. These anti-proliferative responses and the effects on invasion manifested by Dlxin-1, prompted us to analyse, whether activation of MMPs such as MMP-2 and MMP-9 are important in invasion and metastasis of glioma cells. There is a report that overexpression of NRAGE suppresses metastasis of melanoma and pancreatic cancer probably through downregulation of MMP-2.
11 Tumor progression is facilitated by an increased activity of proteolytic enzymes such as MMPs, such as the involvement of MMP-2 and MMP-9 in tumor cell invasion and metastasis in gliomas. 25 Hence, we determined the expression and activity of these proteins in HNGC-2 cells and compared them with Dlxin-1-expressing cells. For this, we used both RT-PCR and gelatin zymography to determine the expression and enzyme activity of MMP-2 in Dlxin-1-overexpressing HNGC-2 cells. The HNGC-2 and HNGC-2 tumor cells showed high levels of MMP-2 expression, visualized as a single 411 bp product by RT-PCR using MMP-2-specific primers (Figure 4b, A) . A significant decrease in MMP-2 expression was however, noted in the Dlxin-1-overexpressing cells. Quantitatively, the expression levels were lower by 1.8-fold for HNGC-2 cells and lower by about 6.25-fold in tumor-derived HNGC-2 cells (Figure 4b, A) . These expression studies very well corroborated with the MMP-2 activity assays performed by gelatin zymography. Here, we found that Dlxin-1-overexpressing HNGC-2 cells showed lower MMP-2 enzyme activity (Figure 4b, B) . We also found a decrease in MMP-9 activity for HNGC-2 cells (Figure 4b, B) . RNA interference using Dlxin-1 siRNA increased expression of MMP-2, which on quantitative analyses amounted to 137% in HNGC-2 cells (Figure 4c ). These studies indicate that the lowered invasiveness occurring because of lowered MMP-2 activity is specifically attributed to presence of Dlxin-1. These studies elaborate that Dlxin-1 induces downregulation of both MMP-2 and MMP-9 in CSCs and this leads to inhibition of glioma invasion.
Downregulation of proliferation-associated genes by Dlxin-1
The inhibitory effects of Dlxin-1 on cell proliferation, tumorigenic and invasion potential prompted us to acquire a comprehensive differential global gene expression profile between HNGC-2 and HNGC-2-Dlxin cells using high-throughput cDNA microarrays, and the data in the form of trancriptome analyses is presented in Supplementary Figure S3 . Detailed analyses indicated that Dlxin-1 induced significant changes in the expression of genes associated with cell growth regulation. This data is exemplified by cluster analyses of these genes represented in Figure 5a and is enlisted in Supplementary  Table S1 . A scatter plot for these representative genes is shown in Figure 5b . A marked upregulation of genes involved in tumor suppressor functions such as RAD54L, VHL, TP73, GLTSCR1, ST14, FLJ12438, PANX2 and PANX3, and downregulation of genes involved with proliferation such as RAS, RAP, Egr-1 and metastasisassociated genes such as p311 were found reaffirming the role of Dlxin-1 as an anti-proliferative protein.
P311 identified as a target for Dlxin-1
In an attempt to investigate the targets with which Dlxin-1 may interact in vivo to manifest its biological function, we analyzed the interactions of different proteins with Dlxin-1 26, 27 using an advanced version of the 'kinase pathway database' known as PRIME. Our analyses suggested that a new branch comprising of proteins P311, Frat2, Rrad and Cacng1 are interacting with Dlxin-1 to manifest its growth inhibitory effects (Figure 6a) . Out of these various proteins, we focused on protein P311 as a putative target for Dlxin-1 because of its known role in glioma cell invasion and metastasis. 28 Expectedly, HNGC-2-Dlxin cells showed a lower expression of P311 as compared with HNGC-2-EV cells in a cDNA microarray analyses. A remarkable decrease in P311 expression to the extent of 80±0.0404% was induced by Dlxin-1 as seen with real-time qPCR (Figure 6b, A) and confirmed by loading the PCR products on an agarose gel (Figure 6b, B) . In an independent study aimed at correlating levels of P311 protein with various grades of glioma, we screened different grades of gliomas for P311 expression. Our studies showed higher expression of P311 in higher grades of Gliomas compared with the lower grades (data not shown). Similar findings were manifested by HNGC-2 cells in which we found that these cells show high cytoplasmic expression of P311 but weak Dlxin-1 expression ( Figure 6c ). Next, we analyzed the co-expression of P311 with Dlxin-1 cells using immunocytochemistry in which we found that both these proteins were coexpressed as cytoplasmic proteins only in HNGC-2-Dlxin cells. The scattergram represents the colocalization of Dlxin-1 with P311 protein seen only in cells overexpressing Dlxin-1 (Figure 6c, left, lower panel) . We further investigated whether P311 physically interacts with Dlxin-1 by immunoprecipitation assays using an antibody to P311. A specific pull-down product of Dlxin-1 with P311 was formed specifically only in HNGC-2 Dlxin cells but not in control cells, confirming that P311 is a specific interacting partner for Dlxin-1 (Figure 6d ). The specificity of interaction was also confirmed by pulling down the respective cell lysates with NRAGE and probing with an antibody to NRAGE (Figure 6d) . The co-expression of P311 with Dlxin-1 as well as their physical interaction provides ample experimental evidence to confirm that P311 is a novel interacting partner for Dlxin-1 and the interactions between Dlxin-1 and P311 possibly block invasive properties of P311 on glioma cells. We in this 
Discussion
Recent studies have identified a small sub-population of tumor-initiating cells or CSCs from Glioma 29, 30 that distinctly possess the ability to self-renew, 1 initiate the tumor in very small cell numbers, drive tumor progression 2 and contribute to therapeutic resistance by expression of several ABC transporters. 31 Hence, strategies that inhibit growth of glioma stem cells and their invasion 32 have immense therapeutic potential in treatment of chemoresistant glioma. The anti-proliferative effects of Dlxin-1 on various cell types such as fibroblasts, 17 breast cancer cell lines and melanomas are already known. We focused on determining whether Dlxin-1 would exert anti-proliferative effects on a chemoresistant cancer stem cell population derived from gliomas and understand the mechanisms through which the effects of Dlxin-1 are manifested. For this study, we used HNGC-2 cell line, as it is a wellcharacterized bona fide glioma cancer stem cell line and were derived as a clonal population that arose by spontaneous transformation of a non-tumorigenic cell line HNGC-1 developed from a glioma tissue. The HNGC-2 cells used here are early-passage cells, derived immediately after spontaneous transformation of HNGC-1 cells and in vitro culture conditions did not induce any chromosomal changes in the genome of these cells.
Gliomas are heterogeneous tumors comprising of a mix of neoplastic and non-neoplastic cells, with extensive diversity amongst tumor cells with differing capacity for in vitro and in vivo growth. 33 Hence, presence of a clonal population of undifferentiated cells satisfying all presently known attributes of CSCs and used at very low passages make HNGC-2 an appropriate system for study. We also substantiated our study using long-term cultures from gliomas of different grades developed by us from clinical specimens. Using these various cell systems we re-affirmed the potential of Dlxin-1 to efficiently inhibit cell proliferation, clonogenicity, cell migration and invasion of glioma cells in vitro as well as in vivo. On the basis of these elaborate studies, we propose that the antiproliferative effects of Dlxin-1 are manifested through the following mechanisms. (1) Dlxin-1 represses the expression and activities of proinvasive genes such as MMP-2 and MMP-9, and thereby inhibits invasion of glioma cells. Tumor invasion is often due to the activities of the metallo-proteinases, which efficiently digest extracellular matrix proteins such as MMP-2. 34 (2) Dlxin-1 induces a decrease in levels of activated cytoplasmic p21. Studies have shown that that is a definitive corelation between decreased expressions of p21 WAF1/CIP1 and increased grades of glioma. 35 We in our earlier studies showed that p21 functions as an inhibitor of cell proliferation in LN-18 glioma cells. 36 It is demonstrated that various transformation events induce downregula- tion of p21, followed by activation of AKT or ERK2, which interacts and phosphorylates p21, thereby promoting p21Cip1 nucleo-cytoplasmic translocation and ubiquitin-dependent degradation, resulting in cell cycle progression. 37 Several studies suggest that localization of p21 (Cip1) to the cytoplasm in transformed cells contributes to pathways that favor not only cell proliferation but also cell motility, thereby contributing to invasion and metastasis. 38 (3) Analyses of effects of Dlxin-1 on global gene expression in glioma cells revealed that Dlxin-1 induces significant downregulation in expression of a large number of oncogenes, such as the small GTP-binding proteins of the RAP and RAS families, members of the E2F and ETS domain family of transcription factors, as well as members of the mitogen-activated protein kinase signaling pathways. Additionally, there was a significant downregulation in expression of genes linked to tumor suppressor function such as the von Hippel-Lindau tumor suppressor gene-VHL gene. The VHL protein has role in various cellular functions, including the regulation of genes involved in control of cell division. 39, 40 Hence, the effects of Dlxin-1 on genes important in cell growth regulation provide vital clues to its role as an anti-proliferative protein on glioma cells. (4) We further establish that a protein P311 involved in glioma cell invasion and growth is a direct target of Dlxin-1 and their interaction results in glioma cell growth inhibition. 41 The Dlxin cells were unable to successfully colonize the brain and very few GFP-positive Dlxin cells that colonized the brain were of a lower proliferative status (Ki67 positivity) and the colonized cells appeared highly differentiated as evidenced by their morphology and expression of glial differentiation marker GFAP. These findings provide evidence about the ability of Dlxin-1 to induce inhibition of cell growth of glioma stem cells and lead to differentiation of tumor stem cells in vitro as well as in vivo in the ortotopic mouse model.
One of the major issues related to use of GBM animal models is that typically the tumors formed using these models form solid nodules at the injection site, which compress rather than invade the surrounding brain. 42 We earlier reported the development of a mouse Orthotopic Xenograft model with HNGC-2 CSCs in which very few of these cells on intracranial implantation formed tumors that resemble the glioma cancer stem cell-like phenotype and recapitulated the most salient pathobiological features of human GBM-like invasive behavior, wider areas of necrosis, high level of vascularization and loss of functional p53. We believe that the HNGC-2 xenograft mouse glioma model developed by us is one of the ideal systems for investigating the role of anti-proliferative molecules on growth and invasion of glioma stem cells. This is particularly so, as few as 1000 HNGC-2 cells are able to form rapidly proliferating and infiltrating brain tumors within 10 days of engraftment, thereby providing an edge over mouse models that require implantation of higher cell numbers to form tumors or models, which demonstrate slower tumor growth, thereby entailing longer observation periods for visualizing the effects on growth and invasion on glioma stem cells. Our results obtained with Dlxin-overexpressing cells suggest that the HNGC-2 orthotopic mouse model may be proposed as a predictive and reliable tool in preclinical studies as it recapitulates the most salient pathobiological features reported for human GBM.
Although a more exhaustive study exploring the signaling pathways employed by Dlxin-1 in manifesting its anti-tumorigenic potential are necessary, we propose that molecules such as Dlxin-1 with strong anti-tumorigenic potential offer fresh vistas in treatment of cancers that are so refractory to conventional treatment regime.
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